| Acute heart failure with low cardiac output: can we develop a short-term inotropic agent that does not increase adverse events? | |
| | |
MedLine Citation:
|
PMID: 20625945 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Acute heart failure represents an increasingly common cause of hospitalization, and may require the use of inotropic drugs in patients with low cardiac output and evidence of organ hypoperfusion. However, currently available therapies may have deleterious effects and increase mortality. An ideal inotropic drug should restore effective tissue perfusion by enhancing myocardial contractility without causing adverse effects. Such a drug is not available yet. New agents with different biological targets are under clinical development. In particular, istaroxime seems to dissociate the inotropic effect exerted by digitalis (inhibition of the membrane sodium/potassium adenosine triphosphatase) from the arrhythmic effect and to ameliorate diastolic dysfunction (via sarcoendoplasmic reticulum calcium adenosine triphosphatase activation). Additionally, the myosin activator omecamtiv mecarbil appears to have promising characteristics, while genetic therapy has been explored in animal studies only. Further investigations are needed to confirm and expand the effectiveness and safety of these agents in patients with acute heart failure and low cardiac output. |
| | |
Authors:
|
Umberto Campia; Savina Nodari; Mihai Gheorghiade |
Related Documents
:
|
14622625 - Specialist nurse supervised in-hospital titration to target dose ace inhibitor--is it s... 16373465 - Aldosterone antagonists in the treatment of heart failure. 19725445 - Proteomic analysis identifies mitochondrial metabolic enzymes as major discriminators b... 20623185 - Left ventricular remodeling in the post-infarction heart: a review of cellular, molecul... 10870005 - Off-pump coronary artery bypass: early results. 2596415 - Electrophysiologic basis of catheter ablation in atrial flutter. |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Current heart failure reports Volume: 7 ISSN: 1546-9549 ISO Abbreviation: Curr Heart Fail Rep Publication Date: 2010 Sep |
Date Detail:
|
Created Date: 2010-07-19 Completed Date: 2010-10-29 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101196487 Medline TA: Curr Heart Fail Rep Country: United States |
Other Details:
|
Languages: eng Pagination: 100-9 Citation Subset: IM |
Affiliation:
|
Center for Cardiovascular Quality and Outcomes, Northwestern University Feinberg School of Medicine, 645 North Michigan Avenue, Suite 1006, Chicago, IL 60611, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Acute Disease Animals Cardiac Output / physiology* Cardiotonic Agents / adverse effects, pharmacology* Clinical Trials as Topic Digoxin / adverse effects, pharmacology Dobutamine / adverse effects, pharmacology Etiocholanolone / adverse effects, analogs & derivatives, pharmacology Gene Therapy / methods Heart Failure / drug therapy*, epidemiology, physiopathology Humans Hydrazones / adverse effects, pharmacology Pyridazines / adverse effects, pharmacology Ryanodine Receptor Calcium Release Channel / drug effects Sarcoplasmic Reticulum Calcium-Transporting ATPases / drug effects Sodium-Potassium-Exchanging ATPase / antagonists & inhibitors Urea / analogs & derivatives, pharmacology |
| Chemical | |
Reg. No./Substance:
|
0/3-((2-aminoethoxy)imino)androstane-6,17-dione; 0/Cardiotonic Agents; 0/Hydrazones; 0/Pyridazines; 0/Ryanodine Receptor Calcium Release Channel; 0/omecamtiv mecarbil; 131741-08-7/simendan; 20830-75-5/Digoxin; 34368-04-2/Dobutamine; 53-42-9/Etiocholanolone; 57-13-6/Urea; EC 3.6.3.8/Sarcoplasmic Reticulum Calcium-Transporting ATPases; EC 3.6.3.9/Sodium-Potassium-Exchanging ATPase |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Embelin induces apoptosis through down-regulation of XIAP in human leukemia cells.
Next Document: Observation Units in the Management of Acute Heart Failure Syndromes.